CHAMPIONS ONCOLOGY ($CSBR) posted quarterly earnings results for Q1 2027 on Thursday, September 10th. The company reported earnings of -$0.03 per share, missing estimates of -$0.01 by $0.02. The company also reported revenue of $15,230,000, missing estimates of $15,345,900 by $-115,900.
You can see Quiver Quantitative's $CSBR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CHAMPIONS ONCOLOGY Hedge Fund Activity
We have seen 5 institutional investors add shares of CHAMPIONS ONCOLOGY stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 192,225 shares (+880.4%) to their portfolio in Q2 2026, for an estimated $1,184,106
- TOCQUEVILLE ASSET MANAGEMENT L.P. removed 24,016 shares (-7.5%) from their portfolio in Q2 2026, for an estimated $147,938
- DIMENSIONAL FUND ADVISORS LP removed 23,973 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $147,673
- GSA CAPITAL PARTNERS LLP removed 20,978 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $129,224
- NORTHERN TRUST CORP removed 18,022 shares (-39.2%) from their portfolio in Q2 2026, for an estimated $111,015
- O'SHAUGHNESSY ASSET MANAGEMENT, LLC removed 13,031 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $74,928
- MILLENNIUM MANAGEMENT LLC removed 10,203 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $58,667
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
